Cunnane Deirdre A. 4
4 · CATABASIS PHARMACEUTICALS INC · Filed Feb 15, 2019
Insider Transaction Report
Form 4
Cunnane Deirdre A.
SVP, General Counsel
Transactions
- Award
Stock Option (right to buy)
2019-02-13+40,000→ 40,000 totalExercise: $4.39Exp: 2029-02-12→ Common Stock (40,000 underlying)
Footnotes (1)
- [F1]This option was granted on February 13, 2019 and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of February 13, 2019 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month.